Todos Medical Ltd. announced that topline results from the Tollovir Phase 2 clinical trial for the treatment of hospitalized COVID-19 patients will be announced the morning of January 27th, 2022, with a conference call follow-up that will occur after market close. The Company will provide further details regarding the conference call during the week ending January 17, 2022 when it announces the data lock for the trial.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00001 USD | +900.00% |
|
0.00% | -95.00% |
1st Jan change | Capi. | |
---|---|---|
-95.00% | 33.24K | |
-33.32% | 9.17B | |
+21.96% | 4.14B | |
+12.12% | 2.63B | |
-7.20% | 1.95B | |
-26.46% | 1.85B | |
+40.46% | 1.22B | |
+52.92% | 969M | |
-9.17% | 694M | |
-19.58% | 235M |
- Stock Market
- Equities
- TOMDF Stock
- News Todos Medical Ltd.
- Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022